5-Sulfonyl-benzimidazoles as selective CB2 agonists
Bie M P Verbist1, Michel A J De Cleyn, Michel Surkyn
1Johnson & Johnson Pharmaceutical Research & Development, Turnhoutseweg 30, 2340 Beerse, Belgium.
Bioorganic & Medicinal Chemistry Letters
|April 9, 2008
Summary
Researchers developed novel benzimidazole CB2-receptor agonists with high potency and selectivity over CB1 receptors. Compound 14j shows promise for investigating peripherally acting CB2 agonists.
Area of Science:
- Medicinal Chemistry
- Neuroscience
- Pharmacology
Background:
- The endocannabinoid system, including CB1 and CB2 receptors, plays a role in various physiological processes.
- Selective CB2 receptor agonists are sought for therapeutic applications with reduced side effects associated with CB1 receptor activation.
Purpose of the Study:
- To synthesize and characterize novel benzimidazole derivatives as CB2 receptor agonists.
- To explore the structure-activity relationships (SAR) of these compounds.
- To identify a lead compound for further investigation as a selective, peripherally acting CB2 agonist.
Main Methods:
- Synthesis of a novel series of benzimidazole compounds.
- In vitro evaluation of CB2 receptor agonistic activity and selectivity over CB1 receptor.
- Structure-activity relationship analysis based on substituent modifications.
Main Results:
- Compounds exhibited potent CB2 agonistic activity with EC50 values as low as 0.5 nM.
- Excellent selectivity for CB2 over CB1 receptors (>4000-fold) was achieved.
- The size of the 2-position substituent modulated the level of agonism (inverse to full).
- Lead compound 14j was identified with optimized drug-like properties.
Conclusions:
- Novel benzimidazole derivatives are potent and selective CB2 receptor agonists.
- SAR studies provide insights into the design of CB2-selective ligands.
- Compound 14j represents a promising tool for exploring the therapeutic potential of CB2 agonists.
Related Concept Videos
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...